[1] Ginter G, Rieger E, Heigl K, et al. Increasing frequency of onychomycoses--is there a change in the spectrum of infectious agents? Mycoses, 1996,39(Suppl 1):118-122. [2] Gupta AK, Sauder DN, Shear NH, et al. Antifungal agents:an overview. J Am Acad Dermatol, 1994,30(5 Pt 1):677-698. [3] Haria M, Bryson HM. Amorolfine.A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs, 1995,49:103-120. [4] Ryder NS. Terbinafen:mode of action and properties of the sequalene epoxidase inhibition. Br J Dermatol, 1992,126(Suppl 39):2-7. [5] Polak AM. Preclinical data and mode of action of amorolfine. Clin Exp Dermatol, 1992,17(Suppl 1):8-12. [6] Nishiyama Y, Asagi Y, Hiratani T,et al. Morphological changes associated with growth inhibition of Trichophyton mentagrophytes by amorolfine. Clin Exp Dermatol, 1992,17(Suppl 1):13-17. [7] Regli P, Goudard M, Ferrari H.Etude compare'e de la sensibilite'in vitro des Malassezia (Pityrosporum) aux nouveaux antifongiques:terbinafine, ciclopiroxolamine, amorolfine. Bull Soc Fr Mycol Med, 1989,18:51-54. [8] Pittrof F, Gerhards J,Erni W, et al. Loceryl nail lacquer--realization of a new galenical approach to onychomycoses therapy. Clin Exp Dermatol, 1992,17(Suppl 1):26-28. [9] Franz TJ. Absorption of amorolfine through human nail. Dermatol, 1992,184(Suppl 1):18-20. [10] Polak AM. Kinetics of amorolfine in human nails. Mycoses, 1993,36:101-103. [11] Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses(an overview). Clin Exp Dermatol, 1992,17(Suppl 1):61-70. |